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The in vitro activity of iclaprim, a novel diaminopyrimidine derivative, was evaluated against 5,937 recent
gram-positive clinical isolates collected in the United States and Europe. Iclaprim demonstrated potent activity
against Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), beta-hemolytic Streptococcus
spp., and Enterococcus faecalis strains tested. In addition, iclaprim exhibited bactericidal activity against all S.
aureus strains tested, including MRSA.
Staphylococcus aureus strains, including methicillin-resistant
S. aureus (MRSA) strains, beta-hemolytic streptococci (most
commonly Streptococcus pyogenes and Streptococcus agalac-
tiae), and Enterococcus spp. are the principal gram-positive
pathogens responsible for complicated skin and skin-structure
infections (cSSSI). The increasing prevalence of MRSA in
hospital and community settings (5, 20), as well as the potential
for resistance or emergence of resistance during therapy to
drugs such as vancomycin (1, 19), linezolid (9), and daptomycin
(12), underscores the urgent need for additional well-differen-
tiated therapeutic agents (17). Iclaprim is a new-generation
diaminopyrimidine that potently and selectively inhibits bacte-
rial dihydrofolate reductase (DHFR) (11, 18, 21). It was de-
signed by a rational drug design approach based on structural
information available on trimethoprim (TMP), the best known
compound of the diaminopyrimidine class which, either alone
or in its synergistic 1:19 combination with sulfamethoxazole,
has been widely used in medical practice for over four decades.
Iclaprim has been shown to have very potent activity against
gram-positive bacteria that are susceptible to TMP. Iclaprim
inhibits bacterial DHFR in a similar manner to TMP but pos-
sesses higher affinity due to increased hydrophilic interactions
between iclaprim and DHFR (15). Thus, iclaprim may retain
activity against some TMP-resistant isolates, but it would be
lower than that against TMP-susceptible strains.
Unlike TMP, the spectrum of activity of iclaprim is more
focused against gram-positive pathogens, including MRSA
strains. Iclaprim has been shown to be rapidly bactericidal
against these strains and to possess a low potential for resis-
tance development when used on its own, without the syner-
gistic combination of a sulfonamide agent (8). For these rea-
sons, iclaprim is under development as a monotherapy, and an
intravenous formulation of iclaprim has completed two phase
3 trials for the treatment of cSSSI caused by gram-positive
pathogens (11, 16). In addition, an oral formulation of iclaprim
as a step-down therapy for patients with cSSSI is ongoing (16).
We evaluated the potency and bactericidal activity of icla-
prim against a large collection of contemporary gram-positive
isolates from hospitalized patients in the United States (26
centers), the European Union (22 centers), Israel (1 center),
and Turkey (1 center) from 2004 to 2006. In total, 5,937 clinical
isolates representative of predominant gram-positive patho-
gens in cSSSI were tested. All organisms were collected from
skin and soft tissue, bloodstream, and respiratory clinical spec-
imens. The numbers of individual strains for each species
tested are shown in Tables 1 and 2. Susceptibility testing by
broth microdilution, including the appropriate quality controls,
was performed according to the documents CLSI M7-A7 (2)
and CLSI M100-S18 (3). Antimicrobial agents tested included
iclaprim (Arpida Ltd., Reinach, Switzerland) and comparators.
Minimum bactericidal concentration (MBC) values were de-
termined for 101 randomly selected strains. MBC experiments
were performed by plating the broth from wells from at least
five log2 dilutions from the MIC (13, 14) onto growth medium.
The lowest concentration of the antimicrobial that killed
99.9% of the starting test inoculum was defined as the MBC
endpoint. Cidality was defined as an MBC/MIC ratio of 4. In
all cases, the thymidine content of the test medium was as-
sessed to ensure that no artifactual inhibition of iclaprim ac-
tivity occurred (2, 6).
Numbers of strains and activity summaries of all drugs tested
are shown in Table 1. Whereas the vast majority of methicillin-
sensitive S. aureus (MSSA; 1,513 strains) strains were suscep-
tible to most of the compounds tested in this study, a large
proportion of MRSA strains were resistant to erythromycin
(84.3%), clindamycin (47.0%), and both quinolones tested
(83.1% and 82.4% for ciprofloxacin and levofloxacin, respec-
tively) (Table 1). Iclaprim was highly active against both MSSA
and MRSA (MIC50/MIC90, 0.06/0.12 g/ml for both) (Tables 1
and 2), with 98.7% of MSSA strains and 94.6% of MRSA
strains being inhibited at a MIC of 2 g/ml (Table 2). For
group A streptococci (GAS), resistance rates to erythromycin,
clindamycin, and tetracycline were higher in the European
Union isolates (26.1%, 5.9%, and 14.2%, respectively) than
those isolated in the United States (6.0%, 0.7%, and 5.0%,
respectively; data not shown). Iclaprim inhibited 100% of GAS
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TABLE 1. Activity of iclaprim and comparator agents tested against Staphylococcus aureus isolates from the United States and the
European Union
Organism and antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % Susceptible/
resistant isolatesa50% 90% Range
S. aureus (4,516)
Methicillin-sensitive (1,513)
Iclaprim 0.06 0.12 0.008–8 /
Trimethoprim 1 1 0.06–64 98.7/1.3
Trimethoprim-sulfamethoxazole 0.06 0.06 0.015–8 99.3/0.7
Erythromycin 0.25 4 0.12–4 77.9/21.1
Clindamycin 0.12 0.12 0.12–4 96.4/3.4
Tetracycline 0.5 0.5 0.5–16 95.8/4.0
Ciprofloxacin 0.5 1 0.12–4 92.0/5.9
Levofloxacin 0.25 0.5 0.12–4 94.2/5.6
Linezolid 2 2 0.5–2 100.0/
Vancomycin 1 1 0.5–2 100.0/0.0
Methicillin-resistant (3,003)
Iclaprim 0.06 0.12 0.004–8 /
Trimethoprim 1 2 0.06–64 92.9/7.1
Trimethoprim-sulfamethoxazole 0.06 0.25 0.015–8 96.1/3.9
Erythromycin 4 4 0.12–4 14.6/84.3
Clindamycin 0.12 4 0.12–4 52.7/47.0
Tetracycline 0.5 16 0.5–16 86.5/12.8
Ciprofloxacin 4 4 0.12–4 16.3/83.1
Levofloxacin 4 4 0.12–4 16.8/82.4
Linezolid 2 2 0.25–2 100.0/
Vancomycin 1 1 0.5–2 100.0/0.0
Beta-hemolytic streptococci (808)
Group A (604)
Iclaprim 0.015 0.03 0.004–0.12 /
Trimethoprim 0.25 0.5 0.03–2 /
Trimethoprim-sulfamethoxazole 0.06 0.12 0.015–0.25 /
Erythromycin 0.12 4 0.12–4 83.3/16.1
Clindamycin 0.12 0.12 0.12–4 96.4/3.3
Tetracycline 0.5 0.5 0.5–16 90.2/9.6
Levofloxacin 0.5 1 0.25–2 100.0/0.0
Vancomycin 0.5 0.5 0.5–1 100.0/
Linezolid 1 1 0.5–2 100.0/
Penicillin 0.06 0.06 0.06 100.0/
Group B (204)
Iclaprim 0.12 0.25 0.015–0.5 /
Trimethoprim 1 4 0.25–8 /
Trimethoprim-sulfamethoxazole 0.06 0.12 0.03–0.25 /
Erythromycin 0.12 4 0.12–4 73.0/26.0
Clindamycin 0.12 4 0.12–4 88.7/10.3
Tetracycline 16 16 0.5–16 21.6/77.9
Levofloxacin 0.5 1 0.25–4 99.5/0.5
Vancomycin 0.5 0.5 0.5 100.0/
Linezolid 1 1 0.5–2 100.0/
Penicillin 0.06 0.06 0.06 100.0/
E. faecalis (310)
Iclaprim 0.015 4 0.004–8 /
Trimethoprim 0.25 64 0.03–64 /
Trimethoprim-sulfamethoxazole 0.03 8 0.008–8 /
Erythromycin 4 4 0.12–4 13.5/52.9
Clindamycin 4 4 0.12–4 /
Tetracycline 16 16 0.5–16 28.4/71.3
Ciprofloxacin 1 4 0.25–4 64.8/34.2
Levofloxacin 1 4 0.25–4 65.2/34.2
Teicoplanin 0.5 0.5 0.5–16 98.4/1.0
Vancomycin 1 2 0.5–16 97.7/1.9
Linezolid 1 2 0.5–2 100.0/0.0
Ampicillin 4 4 4 100.0/0.0
E. faecium (303)
Iclaprim 2 8 0.004–8 /
Trimethoprim 32 64 0.03–64 /
Trimethoprim-sulfamethoxazole 8 8 0.004–8 /
Erythromycin 4 4 0.12–4 3.0/84.5
Clindamycin 4 4 0.12–4 /
Tetracycline 0.5 16 0.5–16 67.3/32.0
Ciprofloxacin 4 4 0.25–4 6.9/86.5
Levofloxacin 4 4 0.5–4 14.2/82.2
Teicoplanin 0.5 16 0.5–16 63.4/34.0
Vancomycin 1 16 0.5–16 55.8/43.2
Linezolid 1 2 0.5–8 99.3/0.7
Ampicillin 16 16 4–16 11.9/88.1
a Criteria as published by the CLSI (1). -Lactam susceptibility should be directed by the oxacillin test results. , no criteria have been established by the CLSI (1).
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at an MIC of 0.12 g/ml and an MIC50/MIC90 of 0.015/0.03
g/ml (Tables 1 and 2). After penicillin (MIC50/MIC90, 0.06/
0.06 g/ml) (Table 1), iclaprim was the most active among all
the antibacterial agents tested. Unlike GAS, group B strepto-
cocci (GBS) from the United States showed higher rates of
resistance to erythromycin (39.2% versus 12.7%), clindamycin
(14.7% versus 5.9%), and tetracycline (82.4% versus 73.5%)
than those isolated in the European Union (data not shown).
Iclaprim was also highly potent against GBS (MIC50/MIC90,
0.12/0.25 g/ml; MIC100, 0.5 g/ml) (Tables 1 and 2), and its
activity was not affected by the organisms’ resistance to eryth-
romycin, clindamycin, or tetracycline. As expected, E. faecalis
isolates were generally more susceptible than Enterococcus
faecium isolates to the drugs tested (Tables 1 and 2), and
resistance rates for E. faecalis did not vary much between the
United States and European Union isolates (data not shown).
Resistance rates were generally high among E. faecium isolates
and differed significantly between those from the United States
and European Union. Most notably, resistance to vancomycin
was 70.8% among isolates in the United States compared to
14.8% among non-United States isolates. Iclaprim demon-
strated the typical bimodal activity of its class against entero-
cocci (Table 2). However, it showed high potency (MIC50/
MIC90, 0.015/4 g/ml) (Table 1) against E. faecalis, with
approximately 72% and 97% of the isolates being inhibited at
MICs of2 and4 g/ml, respectively (Table 2). Iclaprim was
also active (MIC50/MIC90, 2/8 g/ml) against E. faecium
(Table 1), and its activity was not affected by resistance to
vancomycin; approximately 58% and 75% of the isolates were
inhibited at iclaprim MICs of 2 and 4 g/ml, respectively
(Table 2).
Iclaprim was bactericidal against the S. aureus strains tested
(Table 3). Against MRSA, iclaprim demonstrated MBC/MIC
ratios of4 for 100% of strains compared to 60% of strains for
vancomycin. Against MSSA, iclaprim and vancomycin demon-
strated MBC/MIC ratios of 4 for 86% of strains (Table 3).
Iclaprim exhibited bactericidal activity against 45.0% of GAS
and 65.0% of GBS, compared to ratios of 32 for vancomycin
for most GAS and 100.0% of GBS tested (Table 3). Against
enterococci, MBC/MIC ratios of 4 were seen in two out of
five E. faecium strains and 3 out of 15 E. faecalis strains for
iclaprim, whereas all the enterococcal strains tested exhibited
MBC/MIC ratios of 32 for vancomycin (Table 3). The bac-
tericidal activity of iclaprim when tested against staphylococci
corroborates the results of previous studies (8, 10). In contrast,
the fact that iclaprim demonstrated higher bactericidal activity
against staphylococci than against streptococci and enterococci
has not been previously reported and warrants further evalu-
ation.
Results from this study support previously reported non-
clinical susceptibility data (4, 7, 21) and demonstrate the po-
tent bactericidal activity of iclaprim in vitro against both MSSA
and MRSA. This finding, together with the high activity of
iclaprim against beta-hemolytic streptococci and enterococcal
species, confirms iclaprim as an important addition to the ex-
isting panel of therapies for the treatment of cSSSI caused by
gram-positive organisms, including MRSA.
This study was funded by Arpida AG (Reinach, Switzerland).
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